Business Context and Reporting Period
Company: Genmab A/S
Filing Type: Form 6-K (Interim Report)
Reporting Period: Six months ended June 30, 2026
Key Context: The period reflects the full impact of the Merus N.V. acquisition closed in December 2025, financed by $5.5 billion in borrowings. The company reported positive Phase 3 results for epcoritamab (EPKINLY) in DLBCL and updated its 2026 financial guidance upward.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $2,051 million | $1,640 million |
| Operating Profit | $555 million | $548 million |
| Adjusted Operating Profit | $656 million | $554 million |
| Net Profit | $356 million | $531 million |
| Net Cash from Operating Activities | $54 million | $349 million |
| Cash and Cash Equivalents | $1,503 million | $1,296 million |
| Total Borrowings | $5,135 million | $0 million |
| Shareholders' Equity | $5,957 million | $5,302 million |
Revenue Composition (6M 2026): Royalties ($1,708M), Net Product Sales ($261M), Milestone/Reimbursement/Collaboration ($82M).
Key Drivers: Royalty revenue increased 24% driven by DARZALEX and Kesimpta. EPKINLY net sales increased 48% to $312 million globally.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 25% ($411M) year-over-year, primarily due to higher royalties from J&J (DARZALEX) and Novartis (Kesimpta), and increased EPKINLY sales.
- Debt Structure: Total borrowings increased to $5.135 billion from zero in the prior year due to the Merus acquisition financing. This resulted in $174 million in interest expense and $43 million in amortization of borrowing fees for the period.
- Operating Expenses: Adjusted operating expenses rose 28% to $1,270 million, driven by investments in the Rina-S and petosemtamab pipelines and commercialization readiness. Acquisition and integration charges totaled $77 million.
- Net Profit Decline: Despite higher operating profit, Net Profit decreased 33% to $356 million. This was primarily due to increased interest expenses from new debt and a reduction in foreign exchange gains compared to the prior year.
- Employee Count: Total employees increased to 3,119 from 2,639, reflecting the Merus acquisition and pipeline expansion.
Guidance, Outlook, and Risks
2026 Full Year Guidance (Revised)
- Revenue: $4,325 - $4,525 million (Midpoint: $4,425M), up from previous guidance of $4,065 - $4,395 million.
- Adjusted Operating Expenses: $2,810 - $2,950 million (Midpoint: $2,880M).
- Adjusted Operating Profit: $1,065 - $1,385 million (Midpoint: $1,225M).
Management Commentary: The CEO highlighted clinical progress for epcoritamab and Rina-S. The improved guidance is driven by higher royalty revenues from DARZALEX and net sales of EPKINLY.
Risks and Contingencies
- Legal Proceedings:
- Chugai Patent Infringement: Four lawsuits filed in Japan regarding EPKINLY patents. Genmab intends to vigorously defend.
- AbbVie Trade Secret Complaint: AbbVie alleges misappropriation of trade secrets regarding Rina-S. An ITC complaint was withdrawn in Q2 2026, but the district court case remains active.
- Financial Risks: Exposure to foreign exchange rates (EUR/DKK vs. USD) and interest rate fluctuations on floating-rate debt.
- Development Risks: Uncertainty regarding clinical trial outcomes and regulatory approvals for late-stage assets like petosemtamab and Rina-S.
Investor Verification Checklist
- Debt Servicing: Verify the impact of $5.5 billion in new borrowings on future cash flows and interest coverage ratios.
- Royalty Concentration: Assess reliance on DARZALEX royalties (approx. $1.3B in 6M 2026) and potential impacts of patent expirations or Halozyme royalty reductions.
- Merus Integration: Monitor the realization of synergies and the amortization schedule for the acquired Merus technology platform ($24M amortization in 6M 2026).
- Legal Outcomes: Track the status of the Chugai patent litigation in Japan and the AbbVie trade secret dispute, as adverse rulings could impact EPKINLY and Rina-S commercialization.
- Cash Flow Quality: Note the significant decrease in operating cash flow ($295M drop) driven by working capital changes and interest payments; verify sustainability of cash generation.